Publications by authors named "L R Suardi"
Article Synopsis
- - Disseminated non-tuberculous mycobacterial (NTM) infections can severely impact patients with weakened immune systems, potentially leading to serious conditions like hemophagocytic syndrome (HPS) if not diagnosed quickly.
- - A case study involved a 63-year-old woman with suspected autoimmune disease who met the criteria for HPS, with Mycobacterium avium isolated from multiple sources including blood and bone marrow.
- - For better treatment outcomes in immunocompromised patients, early detection of mycobacterial infections and HPS, along with appropriate lab testing for drug resistance, is crucial.
We emulated a hypothetical target trial in which hematological subjects cared at the University Hospital of Pisa (Italy) received or not SARS-CoV-2 prophylaxis with tixagevimab/cilgavimab. Subjects who received prophylaxis (cases) were compared to those who did not (controls). The main outcome was SARS-CoV-2 infection in the subsequent 6 months.
View Article and Find Full Text PDFFifty years after the first identification of Toscana virus in Italy: Genomic characterization of viral isolates within lineage A and aminoacidic markers of evolution.
Infect Genet Evol
August 2024
Toscana Virus (TosV) was firstly isolated from phlebotomine in our Institute about fifty years ago. Later, in 1984-1985, TosV infection, although asymptomatic in most cases, was shown to cause disease in humans, mainly fever and meningitis. By means of genetic analysis of part of M segment, we describe 3 new viral isolates obtained directly from cerebrospinal fluid or sera samples of patients diagnosed with TosV infection in July 2020 in Tuscany region.
View Article and Find Full Text PDFReal-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae.
Eur J Clin Microbiol Infect Dis
February 2024
Purpose: Real-world experience with meropenem/vaborbactam (M/V) is limited. Our aim is to report a clinical experience of M/V in the treatment of resistant Gram-negative bacilli.
Methods: This is a prospective observational study including patients hospitalized in the University Hospital of Pisa (March 2021-Jan 2023) with infections by both extended-spectrum β-lactamases (ESBL)-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae (Kp) treated with M/V.
Background: Metallo-β-lactamase (MBL)-producing Enterobacterales are increasing worldwide. Our aim was to describe clinical features, treatments, and outcomes of infections by MBL-Enterobacterales.
Methods: A prospective observational study conducted in the Pisa University Hospital (January 2019 to October 2022) included patients with MBL-producing Enterobacterales infections.